| 1. |
Zhang Y, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for heart failure in China: results from the China heart failure (China-HF) registry. J Card Fail, 2017, 23(12): 868-875.
|
| 2. |
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation, 2020, 141(9): e139-e596.
|
| 3. |
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol, 2022, 79(17): e263-e421.
|
| 4. |
Xiao S, Li Q, Hu L, et al. Soluble guanylate cyclase stimulators and activators: where are we and where to go?. Mini Rev Med Chem, 2019, 19(18): 1544-1557.
|
| 5. |
Nakamura T, Tsujita K. Current trends and future perspectives for heart failure treatment leveraging cGMP modifiers and the practical effector PKG. J Cardiol, 2021, 78(4): 261-268.
|
| 6. |
Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation, 2021, 144(22): e368-e454.
|
| 7. |
Murphy SP, Kakkar R, McCarthy CP, et al. Inflammation in heart failure: JACC state-of-the-art review. J Am Coll Cardiol, 2020, 75(11): 1324-1340.
|
| 8. |
Blanton RM. cGMP signaling and modulation in heart failure. J Cardiovasc Pharmacol, 2020, 75(5): 385-398.
|
| 9. |
Ishii M, Kaikita K, Sato K, et al. Cardioprotective effects of LCZ696 (sacubitril/valsartan) after experimental acute myocardial infarction. JACC Basic Transl Sci, 2017, 2(6): 655-668.
|
| 10. |
Kim GE, Kass DA. Cardiac phosphodiesterases and their modulation for treating heart disease. Handb Exp Pharmacol, 2017, 243: 249-269.
|
| 11. |
Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail, 2012, 14(9): 1056-1066.
|
| 12. |
Klinger JR, Chakinala MM, Langleben D, et al. Riociguat: clinical research and evolving role in therapy. Br J Clin Pharmacol, 2021, 87(7): 2645-2662.
|
| 13. |
Follmann M, Ackerstaff J, Redlich G, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem, 2017, 60(12): 5146-5161.
|
| 14. |
Emdin M, Aimo A, Castiglione V, et al. Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week. J Am Coll Cardiol, 2020, 76(15): 1795-1807.
|
| 15. |
Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA, 2015, 314(21): 2251-2262.
|
| 16. |
Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med, 2020, 382(20): 1883-1893.
|
| 17. |
Ezekowitz JA, O’Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail, 2020, 8(11): 931-939.
|
| 18. |
Rao BR, Dickert NW, Morris AA, et al. Heart failure and shared decision-making: patients open to medication-related cost discussions. Circ Heart Fail, 2020, 13(11): e007094.
|
| 19. |
Senni M, Alemayehu WG, Sim D, et al. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. Eur J Heart Fail, 2022: 5.
|
| 20. |
Ezekowitz JA, Zheng Y, Cohen-Solal A, et al. Hemoglobin and clinical outcomes in the vericiguat global study in patients with heart failure and reduced ejection fraction (VICTORIA). Circulation, 2021, 144(18): 1489-1499.
|
| 21. |
Ruehs H, Klein D, Frei M, et al. Population pharmacokinetics and pharmacodynamics of vericiguat in patients with heart failure and reduced ejection fraction. Clin Pharmacokinet, 2021, 60(11): 1407-1421.
|
| 22. |
Butler J, Stebbins A, Melenovský V, et al. Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial. Circ Heart Fail, 2022, 15(6): e009337.
|
| 23. |
Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation, 1998, 98(10): 946-952.
|
| 24. |
Gopinathannair R, Chen LY, Chung MK, et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American Heart Association. Circ Arrhythm Electrophysiol, 2021, 14(6): HAE0000000000000078.
|
| 25. |
Ponikowski P, Alemayehu W, Oto A, et al. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. Eur J Heart Fail, 2021, 23(8): 1300-1312.
|
| 26. |
Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (vericiguat global study in subjects with HFrEF) trial. Eur J Heart Fail, 2021, 23(8): 1313-1321.
|
| 27. |
Boettcher M, Loewen S, Gerrits M, et al. Pharmacodynamic and pharmacokinetic interaction profile of vericiguat: results from three randomized phase I studies in healthy volunteers. Clin Pharmacokinet, 2021, 60(3): 337-351.
|
